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Abstract 
Introduction: The last 20 years have seen significant improvements in the analytical capabilities of 
biological mass spectrometry (MS). Studies using advanced MS have resulted in new insights into cell 
biology and the etiology of diseases as well as its use in clinical applications. 
Areas covered: This review discusses recent developments in MS-based technologies and their cancer-
related applications with a focus on proteomics. It also discusses the issues around translating the research 
findings to the clinic and provides an outline of where the field is moving. 
Expert commentary: Proteomics has been problematic to adapt for the clinical setting. However, MS-based 
techniques continue to demonstrate potential in novel clinical uses beyond classical cancer proteomics. 
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1. MS-Based Cancer Proteomics – An Overview 
The field of mass spectrometry (MS)-based proteomics has undeniably contributed to our knowledge of 
biological systems and has allowed us to characterise them in far greater detail than would have been 
possible using conventional analytical strategies. In the field of cancer research alone, there have been over 
12,000 research and review articles published in the last 20 years where the term proteomics is cited, with 
the vast majority reporting data obtained by MS analysis. MS-based technologies have been used to study 
the molecular mechanisms of cancer through examination of specific gene function and regulation, to 
interrogate deregulated signalling pathways in cancer, to define molecular sub-types of tumours, to map 
cancer-associated protein interaction networks and post-translational modifications, to aid in the 
development of new therapeutics or imaging tools and particularly of new diagnostic and prognostic tests 
through the identification of cancer biomarkers. 
In the study of the molecular mechanisms of cancer, proteomic profiling is frequently employed to 
compare the relative abundances of proteins between two or more relevant biological or clinical samples 
and thereby to infer the involvement of particular proteins in specific biological processes that contribute 
to cellular transformation or cancer progression. Samples from a variety of sources have been used 
including cultured cell models, mouse models, primary cells, tumour tissues and body fluids such as serum, 
plasma, urine and bile. Profiling of biospecimens has to date largely employed ‘bottom-up’ MS approaches, 
where at some point in the workflow the protein sample is proteolytically digested into its constituent 
peptides prior to MS analysis: peptides are more amenable to identification and chemical characterisation 
using MS (Figure 1). Liquid chromatography (LC) electrospray ionisation (ESI) tandem mass spectrometry 
(MS/MS) is the method of choice for bottom-up proteomics, with improvements in MS instrument speed, 
sensitivity, mass accuracy and resolution now providing an unparalleled depth of coverage of the proteome 
and allowing detailed chemical characterisation of multiple proteoforms [1-3]. 
Extensive fractionation and/or enrichment are usually required to achieve high-depth coverage of 
complex biological specimens. Bottom-up proteomics has been largely driven by data-dependent 
acquisition (DDA), where the most abundant peptide precursor ions entering the mass spectrometer are 
selected for fragmentation and identification. Since tandem instruments have a finite cycle time, not all 
peptide ions can be selected, resulting in considerable under-sampling. Increasing resolving power through 
orthogonal multidimensional LC separation is thus required to simplify the mixture of peptide ions entering 
the analyser at a given time during the chromatography such that under-sampling and ion suppression are 
minimised and dynamic range can be improved [4] (Figure 1). Whilst the analysis of multiple fractions is a 
necessity for improving coverage, it comes at the cost of longer analysis times. However, continued 
improvements in instrument sensitivity, selectivity and speed are now making high-coverage analysis of low 
amounts of complex samples possible without the need for extensive fractionation and/or analysis time. 
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In ‘top-down’ proteomics, protein identification is obtained directly from fragmentation (and possibly 
other information) of the intact proteins. Theoretically, this provides the richest data for both identification 
and full characterization of molecular composition and is a useful targeted approach for the study of 
cancer-associated proteins. However, it is considerably more challenging to execute than bottom-up 
approaches because of the complexity of the data generated and is generally restricted to proteins <30 kDa 
due to MS resolution limitations and offers lower proteome coverage of complex samples. Despite this, a 
top-down approach was shown to provide additional molecular information when combined with a 
bottom-up approach in the characterisation of patient-derived xenograft models of different breast tumour 
sub-types [5]. 
Proteomic profiling by LC-MS/MS must incorporate a means of quantification and numerous methods 
have been reported [6]. Briefly, they fall into two categories: label-free and those using protein or peptide 
labelling, known as differential mass tagging or isotopic labelling (Figure 1). Most strategies employ relative 
quantification, although methods for absolute quantification are possible through the introduction of 
known amounts of internal standards, as used in methods such as selected and multiple reaction 
monitoring (S/MRM), which are discussed later. Label-free approaches involve comparison of peptide ion 
signal intensities between samples or comparison of spectral counts for peptide ions matching a particular 
protein. In terms of quantitative accuracy, label-free approaches are more dependent on chromatographic 
reproducibility requiring detection and matching of the same ions across runs [7]. In contrast, chemical 
labelling strategies such as TMT [8], iTRAQ [9] or dimethyl labelling [10], and in vivo labelling strategies such 
as SILAC [11], rely on the use of stable isotope-labelled reagents that allow mixing of two or more 
differentially labelled samples prior to LC-MS, with ion signal intensities directly comparable in the same 
MS or MS/MS scans. Use of labelling strategies thus improves throughput and potentially quantitation 
accuracy. Whilst clinical specimens such as tumour tissues and body fluids are generally not amenable to in 
vivo labelling, in vivo-labelled reference material (from relevant cell lines for example) has been used for 
comparative studies, as exemplified by the super SILAC method [12]. Example workflows for LC-MS-based 
profiling in cancer research are presented in Figure 1. 
LC-MS/MS-based protein expression profiling has been recently used to compare the proteomes of 
normal, benign and malignant tissue specimens to a depth of coverage of >9,000 gene products [13,14]. 
Such large-scale studies are implicating the cellular processes and metabolic pathways involved in tumour 
development and progression on a near genome-wide scale. Proteomics has also been integrated with 
genomics, transcriptomics and bioinformatics in so called proteogenomics, providing complementary and 
detailed molecular information linking cancer genotype and phenotype on an individualised level [15,16]. A 
commendable example of this was the profiling of 95 colorectal tumours previously characterised by The 
Cancer Genome Atlas [17]. Somatic variants displayed reduced protein abundance compared to germline 
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variants, whilst copy number alterations or mRNA transcript levels did not reliably predict protein 
abundance across the tumour set. Five proteome subtypes were identified, two of which overlapped with 
previously defined transcriptomic subtypes, but had distinct mutation, methylation and protein expression 
patterns associated with clinical outcome. Several potential driver genes were also identified. By 
overcoming disparities between mRNA and protein abundances and by allowing the identification of 
tumour-associated post-translational modifications, proteomics has the potential to identify novel gene 
products involved in malignancy, to determine therapeutic targets and to facilitate the discovery of novel 
diagnostic and prognostic markers. It is important to note here that bioinformatics analysis of these large 
datasets can only infer the functional involvement of differentially expressed proteins in cancer-specific 
processes and the onus is now on researchers to functionally validate the findings of these studies. 
The analysis of biofluids by MS-based proteomics is particularly challenging owing to their very broad 
dynamic range of protein abundance. A way to improve coverage in DDA has been to immunodeplete the 
most abundant proteins using immobilised antibodies [18]. Whilst concerns have been raised about the loss 
of protein species bound to proteins targeted for depletion and the reproducibility of parallel depletions, it 
is generally accepted that the increased coverage afforded by immunodepletion outweighs these 
shortcomings. Immobilised combinatorial peptide libraries have also been used to ‘equalise’ protein 
abundances in biofluid specimens and work by presenting a limited number of binding sites for 
theoretically all proteins in the sample [19]. Binding sites for abundant proteins become saturated and 
excess of these proteins are removed, whilst lower abundance species are enriched. However, by its 
concept this approach is inherently limited for quantitative analyses. 
The enrichment of specific sub-proteomes such as phosphoproteins and glycoproteins has also been 
used to improve the depth of coverage and identify expression changes and alterations in post-translational 
modifications relevant to cancer. Various methods for sub-proteome enrichment have been reviewed in 
more detail elsewhere [20-23]. In one example, phosphopeptide enrichment and TMT-labelling were used 
with LC-MS/MS to profile pancreatic tumour and adjacent normal tissue specimens [24]. Tumour-specific 
changes in protein expression and phosphorylation were revealed. Activator phosphorylation sites on 
several known drug targets implicated them as targets for individualised therapy. In another impressive 
example, the response of 13,405 phosphopeptides to a panel of small-molecule kinase inhibitors was 
assessed using a label-free approach [25]. The study revealed the topology and activity of different 
signalling networks and showed how kinase networks were remodelled in inhibitor-resistant cells reflecting 
their evolved phenotypes. Lectin affinity enrichment or hydrazide chemistry capture combined with 
enzymatic release of glycopeptides coupled with quantitative LC-MS/MS has been used for the 
identification of altered N-glycosylation and glycoprotein expression in a variety of cancer types [26-29], 
whilst identification of substrates and altered activities of tumour-specific proteases has been achieved 
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using peptide library screening, exogenous reporter substrates or labelling and enrichment of protease-
generated N-termini [30]. 
MS has also become an indispensable tool for characterising immunopeptidomes, i.e. the collection of 
peptides associated with and presented by human leukocyte antigen (HLA) molecules [31,32]. Using cancer 
cell models or clinical specimens combined with various enrichment methods, it is now possible to rapidly 
and comprehensively define the repertoires of cancer-associated peptides presented by HLA molecules. In 
a recent example, immunoprecipitation and LC-MS/MS in DDA mode was used to define acute myeloid 
leukaemia (AML)-associated peptide vaccine targets by comparing eluted peptides from AML patient and 
healthy donor mononuclear cells [33]. Over 25,000 different presented ligands were identified and 
prioritised based on AML exclusivity and presentation frequency. Functional characterisation of tumour-
associated peptides confirmed AML-specific T-cell recognition. These types of study are providing the 
knowledge to guide the development of novel anti-cancer immunotherapies [34]. 
MS-based metabolic profiling is worth mentioning here in the context of exploring the mechanisms of 
cancer and for cancer biomarker discovery. Solvent extraction, protein removal and chemical derivatisation 
are coupled with LC–MS/MS and/or GC-MS to acquire metabolite profiles from any sample type, with 
molecular identification and quantification achieved using spectral libraries and labelled standards [35]. As 
examples in the cancer field, metabolomic profiling was used to identify sarcosine as a driver of prostate 
cancer aggressiveness [36], an ultra-long-chain fatty acid as a potential serum marker of pancreatic cancer 
[37] and (R)-2-hydroxyglutarate as an ‘oncometabolite’ generated by mutant forms of IDH1 and 2 found in 
cancer [38]. In the near future, the integration of metabolomic and proteogenomic information will provide 
a truly holistic view of biological systems, allowing the linkage of genotype with phenotype on an individual 
level that will drive personalised medicine. 
 
2. Proteomic Cancer Biomarker Discovery – The Failure of Proteomics and Solutions 
Cancer biomarkers are categorised by their ability to discriminate malignancy from the healthy or 
benign state, and thereby can be used for diagnosis, early detection and monitoring disease recurrence. 
Biomarkers can also be used for prognosis or to predict response to therapy, and may also aid in 
understanding the biological mechanisms underlying tumour development and progression. One research 
area where MS-based proteomics is used intensively is in cancer biomarker discovery (e.g. [39-43]), yet the 
field of MS-based proteomics has delivered few cancer biomarkers that have been translated to clinical use 
[44]. It may be the case that the ‘best’ tumour markers have already been found and further discovery, 
even at a level covering the whole proteome with detailed characterisation of all proteoforms, will be 
fruitless. However, there is still hope since it is likely that the performance of existing biomarkers (e.g. PSA, 
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CA125, CEA and CA19-9) could be improved by combining them with additional markers and using novel 
biomarker modelling methods. 
Cancer is a complex and heterogeneous disease and this certainly contributes to the failure of 
proteomics in delivering useful biomarkers. Related to this, any specific tumour type is likely to display 
different molecular characteristics from one patient to another patient with individuals responding 
differently to the presence of the tumour. Such differences are largely driven by genetic and epigenetic 
variation, so the emerging technologies and approaches that combine proteomics, genomics, epigenomics 
and metabolomics are likely to benefit biomarker discovery enormously through the investigation of 
molecular changes at an individualised level. In turn, personalised medicine will benefit from an 
individualised biomarker-based approach. 
In addition to the inherent molecular heterogeneity of cancer, the reasons for the failure of MS-based 
and indeed targeted proteomic approaches to deliver biomarkers are centred on the limitations of current 
proteomic strategies and compromises in study design. Below, we discuss these limitations and offer 
suggestions on how to improve the chances of successful cancer biomarker discovery. We also provide the 
few examples of successes in proteomic cancer biomarker discovery and discuss emerging technologies 
that may improve the success rate. 
Firstly, it is recognised that existing proteomic technologies do not adequately deal with the complexity 
and extremely wide dynamic range of expression of the human proteome. This is a particular issue with 
biofluid specimens such as serum, where the dynamic range of protein abundance may be 10 orders of 
magnitude with relatively few abundant proteins contributing the majority of total protein. Additionally, 
potential tumour-specific proteins secreted or released from a tumour are massively diluted in the 
circulation. In essence, we may be failing to cover the proteome to a sufficient depth of sensitivity and are 
thus missing proteoforms with biomarker potential. Secondly, many published discovery studies have failed 
to employ well-characterised, sufficiently numerous, high-quality or even relevant clinical samples. Case 
control samples should be carefully matched by collection protocol, age, gender, drug use and other 
potential confounding factors. Sufficient numbers of samples should be used to adequately power a study. 
False discovery rates should be reported and corrections made for multiple testing when candidate 
selection is undertaken. Variability introduced by sample handling is of particular concern. For serum 
especially, the low-molecular weight proteome has been shown to be highly sensitive to handling 
conditions [45-48], where differential proteolysis is the main driver of this pre-analytical variability. Thus, 
standardised protocols must be employed to ensure that collection, handling and storage of all samples is 
carried out identically (e.g. see [43,49,50]). This may be difficult to achieve in practice and requires the 
coordinated support of clinicians and research nurses. Tissue heterogeneity also limits the value of 
information available from the proteomic analysis of tumour specimens. Unprocessed tumour tissue 
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specimens are often heterogeneous at the cellular level and are often ‘contaminated’ with blood. 
Microdissection and histopathological examination to confirm cellular purity is thus essential to any 
proteomic discovery effort and methods such as laser-capture microdissection, whilst laborious, can be 
used to procure more homogeneous, high-quality specimens [51]. Proteomic analysis of archived formalin-
fixed, paraffin-embedded (FFPE) specimens has also proved to be a feasible approach for biomarker 
discovery despite concerns about variability in fixation, fixation-induced protein modification and protein 
extraction [52]. The longevity and morphological stability of FFPE tissues, the accumulation of archives 
linked to clinical patient data and pathologist-directed microdissection provides an invaluable resource for 
retrospective biomarker studies employing proteomic technologies. 
Lack of use of appropriate controls is a particular problem in discovery studies and it is essential that 
specimens are selected based on the intended use of the biomarker. For cancer diagnosis in the clinical 
setting, biomarkers must differentiate between cases of malignant and benign disease presenting with 
similar symptoms or that show similar findings upon imaging. Many discovery studies have used only 
healthy control specimens, and since candidate markers may be similarly altered in benign conditions with 
shared indications, potential candidates are likely to lack diagnostic specificity. As an example, an 
appropriately controlled proteomic study showed the influence of obstructive jaundice on the performance 
of diagnostic biomarkers for pancreatic cancer [53]. Similarly, inflammatory response markers are 
repeatedly found in proteomic cancer biomarker studies. Whilst this is undoubtedly due to an inflammatory 
response to the tumour, such markers may lack specificity and should be validated against controls from 
inflammatory conditions. For prognostic biomarker discovery, only specimens from patients with clearly 
defined endpoints should be used, whilst biomarker studies looking at treatment response or recurrence 
benefit greatly from the use of longitudinal samples [54]. In the search for early detection/screening 
markers, samples pre-dating diagnosis should ideally be used. This has been achieved using samples from 
on-going screening programs or trials [42,55] and is a means of reducing the false discovery of late stage, 
non-specific markers.  
Thirdly, and perhaps most importantly, many biomarkers or multi-marker classifiers arising from 
proteomic discovery are not properly validated using independent samples or are not compared with the 
gold standard biomarker test. Furthermore, biomarker panels may have failed validation, but are not 
reported. Independent researchers may be wasting effort in reassessing the same potential biomarkers. A 
paucity of open-access biomarker databases does not help and there is need for better standardisation, 
with proof of robustness of biomarker tests in investigator-blinded, multi-institutional trials before uptake 
of the biomarker assay in the clinic [44]. In reporting biomarker studies, guidelines such as STARD and 
REMARK should be adhered to so that reliability and quality can be assessed and biomarkers compared 
across studies; it is clear that many studies fail to follow these guidelines [56,57]. In summary, clearly 
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defining intended use, good study design, appropriate patient specimens and proper validation are critical 
to the success of cancer biomarker discovery efforts and in gaining regulatory approval for their clinical use. 
 
3. Proteomic Cancer Biomarker Discovery - Applications of MS-Based Methods 
MALDI and SELDI linked to time-of-flight (TOF) MS and capillary electrophoresis ESI MS have been used 
extensively in cancer biomarker discovery [58-60]. Linking these methods with robotic liquid handling for 
automated polypeptide extraction and sample spotting allows a rapid, high-throughput means of obtaining 
spectral patterns from various sample types. Using these methods, numerous studies have reported 
spectral patterns and multi-peak classifiers (usually comprising low-mass polypeptide species) that could 
accurately discriminate cancer from control biofluid specimens [61-68]. Whilst these approaches were 
initially heralded as a rapid and accurate means for cancer diagnoses, questions concerning their 
reproducibility, lack of identification of the discriminatory peaks and the robustness of the class-prediction 
algorithms employed have since cast doubt on the validity of some studies [69,70]. The lack of 
reproducibility is in part associated with the stability of the low-mass proteome and its sensitivity to pre-
analysis sample handling conditions (see above). In serum at least, the diagnostic peaks identified are 
chiefly fragments of abundant coagulation, complement and apolipoproteins [71], generated through the 
action of proteases during clotting. Whilst it has been proposed that tumour-specific exopeptidases or 
dysregulated haemostasis may generate these diagnostic peptide signatures [72,73], other studies have 
failed to find high-accuracy discriminatory signatures [74,75]. Despite this negative viewpoint, two 
discoveries made using SELDI- and MALDI-TOF MS have progressed to commercialised biomarker tests 
[67,76]. The OVA1 test may have clinical utility in discriminating benign from malignant pelvic masses 
observed by ultrasound, although notably immunoassays were ultimately used for the approved test as the 
reproducibility of the discovery SELDI-TOF platform was deemed inadequate for routine clinical use. The 
MALDI-TOF-based VeriStrat test has prognostic utility and to guide second-line therapy choice in non-small 
cell lung cancer. 
Quantitative LC-MS/MS in DDA mode has been used extensively for profiling biofluid samples and offers 
a higher depth of coverage than the TOF MS-based approaches outlined above. Whilst the number of 
reported studies is huge, and protein coverage is ever-increasing, virtually all studies to date have failed to 
provide accurate cancer biomarker panels suitable for clinical use. The main reasons for this are outlined in 
the section above. The secretomes of engineered cell models or tumour-derived cell lines may offer a more 
consistent matrix for the identification of specific biomarker candidates using LC-MS/MS profiling [77-85]. 
In one study, mutated tryptic peptides derived from cancer-mutated proteins were identified from the 
secretomes of multiple colorectal cancer cell lines using a bespoke mutant protein database [79]. These 
mutated proteins have the potential to serve as highly specific tumour markers. Genetically engineered 
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mouse models have also been used for the discovery of human cancer biomarker candidates [86]. Mouse 
models offer a more homogeneous genetic background and permit sampling from defined tumour stages 
and mutant sub-types. As the sensitivity of proteomic methods continues to increase, it is now possible to 
conduct high-coverage discovery studies using very small amounts of clinical material. For example, a depth 
of coverage of 10,000 proteins per specimen was achieved by profiling adenoma and paired colorectal 
cancer and adjacent normal tissue specimens obtained by laser-capture microdissection [14]. The in-depth 
analysis of tumour-proximal specimens, which in theory should be enriched in secreted tumour markers, is 
also a future direction. Examples include nipple aspirates, biliary brushings, bronchoalveolar lavage fluid 
and cyst fluid. Membrane-derived extracellular vesicles (exosomes) may also be an enrichable source of 
tumour biomarkers, with growing evidence that their protein cargoes also play a role in promoting cancer 
and metastasis [87]. In a recent study, MS-based profiling of cancer cell-derived exosomes identified GPC1 
as an enriched protein. The investigators went on to show that GPC1+ exosomes isolated from serum could 
detect pancreatic cancer with absolute specificity and sensitivity [88]. 
Data-independent analysis (DIA) methods have been developed more recently for application in both 
biomarker discovery and verification [89-93]. In DIA methods, the mass spectrometer typically cycles 
through low and elevated fragmentation energy modes over the course of the chromatographic elution and 
the entire m/z acquisition range (e.g., (HD)MSE [94,95]) or through adjacent precursor isolation windows 
(e.g., SWATH [96]), fragmenting all precursor ions together in each elevated-energy full MS scan or isolation 
window. This creates a comprehensive but highly convoluted MS/MS spectral dataset that is in essence a 
permanent digital map of the sample analysed. Spectra are deconvoluted either by time and accurate mass 
matching of chromatographic profiles of precursor and fragment ions or by using high-quality spectral 
libraries of native or synthetic peptides obtained in DDA mode. Quantitative information can be extracted 
from the digital maps using spiked standards or signals from the spectral libraries. DIA methods have the 
potential to accelerate biomarker discovery by allowing mining of historical spectral datasets for any 
protein and thus to verify candidate biomarkers from other earlier studies [97]. 
The DIA method HDMSE was recently used for discovery of serum markers to discriminate 
cholangiocarcinoma from benign biliary tract disease [98] and resectable pancreatic cancer from benign 
pancreatic disease [99], with reasonable coverage achieved for this difficult matrix. SWATH MS has been 
combined with pressure cycling technology for rapid sample dissolution and proteolysis to generate 
fragment ion maps of 18 biopsy samples from 9 patients with renal cell carcinoma [100]. Over 2,000 
proteins were quantified from the SWATH maps and proteins were identified that could distinguish tumour 
from healthy tissue and discriminate histological subtypes. The same group used SWATH MS to analyse 
isolated N-linked glycopeptides from normal and prostate tumour specimens, searching SWATH maps with 
a spectral library of known N-glycosites [101]. 220 differentially expressed glycoproteins were identified 
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and two (NAAA and PTK7) were validated as potential prognostic biomarkers by tissue microarray analysis. 
Similarly, lectin glycoprotein capture and SWATH MS was used to profile the secreted glycoproteome of a 
model cell system of metastatic colon cancer, identifying LAMB1 as a potential diagnostic marker [83]. 
Finally, in a study searching for tumour markers of oesophageal squamous cell carcinoma, SWATH MS was 
combined with MRM for discovery and verification [102]. Of 1,758 proteins quantified, 467 were 
differentially expressed between normal and tumour tissue with 116 verified by MRM assays which showed 
high correlation with the SWATH MS data. The MRM assays were then conducted in a subset of peptide 
library-equalized serum samples from the same patients, taken pre- and post-operatively. Although the 
success rate of the serum MRM assays was considerably reduced, several candidate biomarkers were 
verified in serum. The speed and sensitivity of new SWATH MS methods is expected to improve, allowing 
use of smaller isolation windows that will reduce interfering peaks and allow more reliable identification 
and quantification of lower abundance peptides. 
 
4. Cancer Biomarker Assays 
Antibody-based protein detection is the most widely used method for protein quantification and 
remains the gold standard for protein assays in the clinical laboratory. However, it can be limited by the 
availability of suitable antibodies of defined specificity. Targeted MS is an analytical technique with high 
specificity, reproducibility and dynamic range and methods such as SRM/MRM on triple quadrupole 
instruments are now used routinely for the accurate measurement of peptides and other analytes in 
biospecimens [103,104]. SRM/MRM enable the measurement of proteotypic peptides that uniquely 
represent the target protein of interest and make use of stable isotope-labelled standard peptides spiked 
into the samples for quantification. Selection of optimal transitions for MRM assays requires significant 
effort, although this has been partly overcome in parallel reaction monitoring on quadrupole orbitrap 
instruments, where all fragment ions of the target peptide ion precursor can be recorded for each charge 
state with selection of optimal fragment ion traces for identification and quantification carried out post-
acquisition [105]. In the biomarker discovery pipeline, MRM is already showing great potential as a tool for 
rapid verification and validation [106,107] and efforts are underway to standardise its use [108]. MRM also 
provides the analytical depth and sensitivity for biomarker analysis from bodyfluids such as urine and saliva 
that can be non-invasively obtained but harbour intrinsically lower amounts of biomarkers than the 
tumour-proximal bodyfluids discussed in the previous section.  
The parallel nature of MRM has raised the possibility that specific assays could be configured and 
multiplexed to measure all human proteins. In a pilot study designed to test the feasibility of large-scale, 
inter-laboratory efforts in this area, 645 novel MRM assays representing 319 proteins were configured and 
multiplexed to quantify endogenous proteins in a panel of breast cancer cell lines across three laboratories 
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[109]. High inter-laboratory correlation and assay precision were reported, and peptide measurements 
were able to discriminate tumour subtypes and identify genome-driven changes in the cancer proteome. 
But are large-scale targeted approaches amenable to biomarker discovery? Targeted proteomics by its very 
nature relies on prior knowledge that the targeted analyte is worth measuring in the first place and this is 
by no means a given. In one recent study, 371 candidate lung cancer biomarkers found from MS-based 
tissue profiling and literature searching were assessed in a three-site discovery and validation study using 
MRM assays [110]. The work identified a 13-protein plasma-based classifier that could differentiate 
patients with malignant and benign lung nodules with high confidence. A modified version of the classifier 
has since been independently validated and provides a clinically useful diagnostic tool to avoid invasive 
biopsy on benign lung nodules [111]. It is becoming evident that combining multiple protein measurements 
together using multi-variate modelling approaches offers a more effective approach in determining an 
individual’s state of health or disease. 
The clinical application of MS will certainly come via its unparalleled analytical specificity. An example of 
this may be the assay of cancer-specific, post-translationally modified proteins, which may be more 
accurate biomarkers for diagnosis and prognosis [112]. However, it is as yet unclear whether targeted MS-
based approaches can be used to accurately assay low-abundance biomarkers in a high-throughput fashion. 
Current tumour markers such as CA125, PSA and CEA are expressed at the mid-pg/mL to low-ng/mL range, 
below the analytical sensitivity of SRM/MRM. A way around this has been to pre-fractionate, 
immunodeplete, or affinity-enrich proteins prior to targeted MS analysis (see above). Affinity-enrichment is 
employed in so-called MS immunoassays, where a protein or peptide is first captured from the biofluid 
sample on immobilised antibodies prior to ESI-MS/MS or MALDI-TOF MS analysis [113-115]. This strategy 
has the added benefit that multiple proteoforms of the target protein can be resolved and characterised 
simultaneously. The methodology also lends itself to automation, facilitating rapid throughput [116]. Whilst 
such methods may suffer from increased technical variation compared to standard immunologic assays and 
will be challenging to standardise in the clinical laboratory, their use in research is becoming more 
widespread as reagents are developed and analytical sensitivity improves. 
 
5. Mass Spectrometry Imaging (MSI) 
Although mass spectrometry imaging (MSI) of biomolecules was introduced more than two decades ago its 
development and application was mainly focused on tissue analysis of animal models. It took the best part 
of two decades to develop the sample preparation and ion sources for this technology to achieve the 
spatial resolution, sensitivity and versatility to become a competitive imaging technique in clinical 
diagnostics and research. By scanning the sample with a well-focused laser beam and acquiring individual 
mass spectra from extremely small desorption spots, which is often called the ‘microprobe’ approach (see 
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Figure 2), it is now possible to image lipids from tissue slices with a spatial resolution of less than 10 μm and 
thus achieve single-cell resolution [117,118]. However, using smaller desorption spot (image pixel) sizes for 
improved spatial resolution leads to reduced sensitivity as the total number of ions generated will decrease 
with a smaller desorption spot. In addition, smaller image pixel sizes result in a larger number of pixels, i.e. 
desorption events, for a given image area and therefore an increased acquisition time, often several hours 
even with high-speed scanning systems and high-repetition lasers. To overcome the general problem of the 
relatively long analysis times in MSI there have been recent efforts in establishing the ‘microscope’ 
approach for MSI, which eliminates the need for acquiring individual mass spectra for many small pixels by 
employing ion optics that can image the spatial distribution of all desorbed ions to a space-sensitive 
detector [119]. 
In the context of clinical cancer research and diagnostics all of the above described issues are of 
relevance. For instance, cancer-specific biomolecules (markers) can be of extremely low abundance, and 
analysis times for intra-operative diagnostics are inherently restricted. However, there have been some 
important recent advances in the field of MSI and its application to cancer research and analysis. Most of 
these have been achieved by using MALDI as the ionisation method. Nonetheless, there are other methods 
suitable for MSI of biomolecules such as DESI [120], (cluster) SIMS [121], LESA [122], etc. but virtually all of 
these have not matured to the extent MALDI MSI has, and only a few reports have emerged using these 
techniques in the field of cancer research (e.g., [120]). In contrast, the more general laser 
desorption/ionisation (LDI), of which MALDI is a member belonging to the ‘soft’ ionisation sub-types, can 
certainly take direct advantage of most of the MALDI MSI advances and be an adequate replacement for 
MALDI if the analytes do not require the softness of MALDI as it is often the case for small biomolecules. In 
fact, in this case LDI will have the advantage not to be restricted by the cumbersome MALDI sample 
preparation and its effect on analyte diffusion, which can ultimately limit the achievable spatial resolution. 
Similarly, employing an infrared (IR) laser and exploiting native IR light-absorbing biological matrix 
molecules such as water for native IR-(MA)LDI can be utilised to avoid MALDI sample preparation [123]. IR- 
as well as UV-(MA)LDI have also been used in combination with electrospray to widen the MSI tool box 
further, providing some of the advantages of ESI-generated ions such as higher charge states (e.g., LAESI 
[124], ELDI [125], IR-/UV-MALDESI [126]). In addition, the introduction of atmospheric pressure (AP) MALDI 
ion sources for MSI [118,127] should prove to be advantageous in the future, considering the potential 
need for rapid clinical analysis. 
Currently, the employment of MSI in cancer analysis can be roughly divided into two main areas, i.e. 
(MA)LDI MSI of (i) smaller biomolecules such as lipids, hormones and (drug) metabolites and (ii) proteins 
and proteolytic peptides. (MA)LDI MSI has been particularly powerful and well-demonstrated in mapping 
smaller biomolecules. Lipids but also peptidic hormones and proteins have been useful in defining tumour 
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margins (cf. REIMS – see below) and (intra-)tumour heterogeneity [128-131], presenting an option for fast 
intra-operative decision making in surgery. Cancer drugs and their metabolites such as erlotinib [132] and 
irinotecan [133] have been mapped for various treatments and cancers, particularly in animal models. 
MALDI MSI has also been explored for the analysis of tissue microarrays to predict cancer treatment 
response [134]. Proteins but also lipids have been mapped by MALDI MSI to evaluate their diagnostic and in 
particular prognostic marker potential [135-137], for instance in differentiating and identifying invasive and 
metastatic cancer subtypes. In general, MSI has been unsurprisingly more applied to the analysis of 
common cancers such as breast cancer [134,137-139] and colon cancer [133,135], but in a few cases also to 
rare cancers [140]. That MALDI MSI is more mature than other MSI methods can be seen by the various 
efforts to standardise the technology and to take the next steps to make it a clinically acceptable diagnostic 
method, e.g. by investigating its performance in multicentre studies [138]. Further details on MSI in cancer 
analysis can be found in recent focused reviews [141-143]. 
 
6. MS-Based Cancer Analysis in the Clinic 
As mentioned in the previous section MSI is on the verge of becoming a viable option for intra-operative 
analysis and diagnostics. There are other MS-based technologies that are now entering the field of clinical 
analysis from population screening and clinical microbiology to surgery. In this section MS-based 
technologies are described that are directly related to clinical cancer analysis/diagnostics. 
 
6.1. Rapid Evaporative Ionisation Mass Spectrometry (REIMS) and the ‘iKnife’ 
First introduced in 2009, Rapid Evaporative Ionisation Mass Spectrometry (REIMS) was demonstrated to 
allow the analysis of thermally evaporated ions, particularly phospholipids, from biological samples [144]. 
Building on a previously reported Venturi-type gas jet and polytetrafluoroethylene (PTFE) transfer line 
attached to the mass spectrometer inlet, analyses were performed without close proximity to the 
instrument [145]. An electrosurgical knife fitted to the inlet of the transfer line was used to evaporate 
tissue (see Figure 3), producing a cloud of molecules and clusters in the process. The applicability of the 
mass spectrometer being on-line but remote to the surgical site was expanded upon, particularly with 
regards to real-time analysis of tissue during surgery. Currently, tissue samples must be analysed in a 
separate laboratory during surgery. The patient remains anesthetized while analysis is performed, typically 
a 20-30 minute process which might require repeating. With near-instantaneous feedback by REIMS 
analysis there is potential for reducing surgery times, benefitting patients and hospitals alike. The 
comparison of tissue to library profiles with multivariate analysis allows for on-line discrimination of tissue 
types (e.g. healthy vs. cancerous) for highly precise and complete removal of only tumour tissue. This is 
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particularly important in brain (a lipid-rich organ) surgery, where removing more healthy tissue than 
necessary can have dramatic effects on a patient’s cognitive function. 
The classification of REIMS spectral profiles of tissues by principal component analysis (PCA) was 
demonstrated with healthy and cancerous canine breast tissue, exploiting the fact that the phospholipid 
composition of cancerous cells significantly differs to that of healthy cells [146]. A comprehensive initial 
study of intra-operative tissue identification by REIMS confirmed its applicability to surgery [147]. Samples 
from 302 patients were analysed to build a tissue mass spectral profile database (1,624 cancerous and 
1,309 noncancerous entries). Data from samples acquired in surgery underwent multivariate analysis with 
respect to this database. A total of 81 surgical samples were analysed, which also underwent post-
operative histological diagnosis. A 100% of these samples matched the results from the traditional tissue 
identification method. 
The evolution of REIMS, particularly the electrosurgical ’iKnife’, has captured the attention of the 
broader community [148-150]. REIMS and the ‘iKnife’ concept has been commercialised and a research 
version has already hit the market [151,152]. An endoscopic modification to this concept has also been 
reported recently for the in-vivo analysis of gastrointestinal polyps. By following a similar workflow to other 
REIMS studies in terms of data analysis, healthy intestinal wall tissue, cancerous, and adenomatous polyps 
were distinguished by their REIMS spectra. Compatible with current endoscopic apparatus, this allows 
REIMS to be applied in a relatively less invasive process. The authors propose that this could allow for the 
development of an endoscopic in situ tool for bacterial analysis, since REIMS has also shown promise as a 
bacterial identification technique [153,154]. 
REIMS has recently also been employed for MSI [155]. Currently, there is poor spatial resolution 
(approximately 500 μm) compared to MALDI MSI, which is an issue particularly for tissue with high 
heterogeneity. The physical probe nature of REIMS also resulted in cross-contamination of cancerous 
regions with healthy tissue, an issue not experienced with DESI MSI in the same article. In general, this is an 
inherent weakness of REIMS probes and presumably a difficult problem to solve. The usefulness of REIMS 
for MSI and other applications also relies on its further development to encompass additional molecule 
classes beyond lipids. At this early stage of development, the advantages offered by the more established 
MSI techniques are considerable. 
 
6.2. Lasers and other surgical tools as part of an MS analysis system 
The use of lasers [156] and ultrasound-based [157] surgical tools has also been explored. Lasers in 
particular are of interest because they remove the issues of a physical contact probe and its contamination, 
reducing the potential for sample carry-over. The laser approach relies on the absorption of laser energy 
and localised Joule heating to desorb material, a complex process when one considers the variety of 
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molecules present in a biological sample. Laser energy per pulse was required to be in the order of mJ, 
approximately three orders of magnitude greater than that required for MALDI MS. However, MALDI 
requires a matrix compound to facilitate the efficient absorption of the laser’s energy, but this is not 
compatible with an in-vivo approach to sampling. 
 
6.3. MS biotyping 
A very recent example where MS has been revolutionary in clinical analysis can be found in the area of 
clinical microbiology [158]. Comprehensive MALDI MS-based analytical systems have been introduced to 
the clinical microbiology in-vitro diagnostics (IVD) market and achieved CE (Conformité Européenne)-IVD 
certification and FDA (US Food and Drug Administration) approval as medical devices. These systems have 
been primarily used to biotype (analyse/identify) microorganisms in a typical clinical microbiology setting. 
As such there have been only a few studies where their potential use in cancer analysis has been 
investigated such as in bacterial infections that are linked to higher cancer incidences. For instance, a 
recent study has investigated the identification capability of these systems for Helicobacter pylori, which is 
a Gram-negative, microaerophilic bacterium found in the stomach and associated with gastric cancer for 
specific genotypes [159]. 
 
7. Outlook and Conclusion 
Although mass spectrometry has been a major tool for decades in clinical research, analysis and diagnostics 
(e.g. LC-MS/MS in new-born screening), its application to oncology and clinical cancer analysis in general 
has just begun. Certainly, the long-established clinical mass spectrometry methods are also applicable to 
cancer as one of the many diseases modern healthcare has to cope with, but in many cases their 
applicability is limited to the intricacies and complexity of cancer, as well as the low abundance of the 
cancer-specific protagonists whose detection and identification could lead to new therapies and 
diagnostics. 
While classical mass spectrometry and its advances in sensitivity, quantitation and throughput are 
extremely helpful in analysing cancer-specific low-abundant target molecules (e.g. in cancer proteomics) 
and thus the backbone of MS-based cancer research and analysis, many of the new MS-based methods 
now entering the clinic exploit new concepts in MS analysis such as mass spectral profiling (e.g. biotyping) 
and MSI. In these areas further advances can be expected, in particular with respect to data mining 
software and databases and technological improvements such as space-sensitive ion detection for 
‘microscope’ approaches in MSI. 
In general, mass spectrometry has also the advantage to be able to cater for extremely different types of 
clinical diagnosis, e.g., the more population-wide early diagnosis of disease through screening tests and the 
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highly individualised care in precision medicine and individual treatment such as surgery. Both are of 
utmost importance in cancer diagnosis and treatment as early accurate cancer detection still provides the 
best prognosis for patients due to more effective interventions at an early stage, while cancer therapy and 
surgery can also greatly benefit from the power of MS in providing rapid analyses of a patient’s molecular 
profiles, thus enabling accurate and fast treatment decisions for the individual patient. 
New approaches afforded by MS such as screening - possibly of MS-identified and validated biomarkers, 
but ultimately measured by other means such as immunological assays -, MSI-based pharmacokinetics and 
pathology or precision surgery using an ‘iKnife’ will be invaluable in future cancer research and analysis. 
However, there is still room for improvement for all of the new approaches: for instance, greater analyte 
range in REIMS, faster data acquisition and a more physiological sample environment in MSI, better 
validation of MS-identified biomarkers, and of course, higher sensitivity and quantitation accuracy in all 
cases. Nonetheless, these new approaches have provided another recent wave of advances in clinical mass 
spectrometry with cancer research and analysis the areas benefitting the most. 
Encouragingly, there are even more new approaches in the pipeline such as mass cytometry combined 
with large-scale data mining, another promising MS-based analytical method for precision medicine 
(prognostics) and recently applied to phenotyping of single acute myeloid leukemia cells [160]. Another 
new early-stage approach is MS profiling of breath biomarkers using one of the easiest and least invasive 
sampling of patient-generated biomolecules [161-164]. Thus, it seems that clinical mass spectrometry has 
firmly established itself as a game changer for cancer research and analysis in the years to come. 
 
8. Expert commentary 
Recent years have seen significant improvements in MS instrument speed, sensitivity, mass accuracy and 
resolution. Because of these advances, LC-MS profiling in discovery mode can now provide near whole-
genome coverage of cancer proteomes in relevant cell models and tissue specimens, allowing the detailed 
characterisation of protein expression, mutational status and post-translational modifications. As such, MS-
based protein profiling when combined with genomic, transcriptomic and metabolite profiling is revealing 
the molecular mechanisms and biological processes that contribute to cellular transformation and tumour 
progression at an unprecedented level of molecular detail. Hitherto unknown mechanisms in cancer 
biology are now being elucidated which will hopefully drive the development of novel anti-cancer 
therapies. Moreover, this work is identifying protein changes in patient tissue specimens and biofluids that 
may serve as potential cancer biomarkers. The onus is now on researchers to validate these findings. 
Despite the perceived failure of proteomics to deliver biomarkers with clinical utility, examples of approved 
tests provided in this review show that this is not the case and there is hope that MS-based approaches will 
continue to deliver. However, the learning curve of biomarker discovery must be surmounted before 
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success can be achieved. Problems with study design, sample choice and lack of validation are still major 
issues in many studies. Combining panels of markers using novel mathematical approaches has been shown 
to improve test performances and lends itself to a personalised approach to cancer diagnosis, prognosis 
and therapy choice. The development of rapid MS-based assays capable of very precisely identifying and 
quantifying proteotypic peptide ions, and allowing the detailed chemical characterisation of distinct 
proteoforms with biomarker potential is beginning to circumvent the need for immunological assays, where 
specificity is not guaranteed. However, analytical sensitivity must be improved before MS-based assays can 
replace immunoassays for accurate quantification of protein biomarkers in complex matrices. Tests must 
be appropriately validated in multicentre, prospective trials and shown to outperform the gold standard 
tests before they can be considered for uptake in the clinic. The challenge will then be to make such tests 
technically robust, easy to run and high-throughput for the clinical laboratory. 
Beyond the areas and issues related to MS-based cancer biomarker discovery and assay development there 
are other fields and opportunities opening up for mass spectrometry to become an important tool in cancer 
analysis, in particular as a diagnostic tool in clinical laboratories and even within the operating theatre. The 
former has already been proven to be a game changer in clinical microbiology, quickly achieving the status 
of a fully approved medical device, while the latter has now gone beyond the proof-of-principle stage. 
These are just two more examples where MS has demonstrated its analytical superiority in speed, 
specificity and breadth of (untargeted) analysis. All these characteristics will further advance its place in 
clinical cancer research and analysis. 
 
9. Five-year view 
In the next five years further advances in both the MS-based technologies and their applications will 
certainly feed through to cancer-related research and clinical applications. New putative biomarkers or 
biomarker panels (and their screening potential in combination with or without established and future non-
MS screening modalities) will be found and the prospect of MS-based clinical diagnostics and prognostics 
will further excite the field. However, five years is a short time frame for any major changes in the clinical 
arena. Thus, how far new cancer biomarkers or IVD devices developed with the help of MS will be validated 
and approved in this time frame remains to be seen. In this context it is important to note that the 
introduction of new medical devices and tests has to undergo a stringent approval process and therefore 
any progress in utilizing MS-based discoveries or technologies in oncology are difficult to predict. Progress 
will highly depend on the quality of the supporting data and its acquisition, the potential in improving 
diagnostic accuracy and speed and, last but not least, the willingness to embrace new technology in the 
clinic. 
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10. Key Issues 
• Mass spectrometry (MS)-based cancer proteomics and metabolomics have continued to evolve and 
mature for biomarker discovery. 
• Limitations and problems with study design, sample choice and lack of validation have hindered the 
adoption of these into the clinical setting. 
• Established MS methods, including MALDI-TOF MS, SELDI-TOF MS, LC-ESI MS/MS have all found 
utility. 
• The use of new Data-Independent Analysis (DIA) methods, e.g. HDMSE, SWATH opens up further 
avenues of investigation. 
• Laser desorption MS techniques such as MALDI Mass Spectrometry Imaging (MSI) are increasingly 
found in cancer research and analysis. 
• Novel techniques such as REIMS and biotyping continue to demonstrate the evolution of mass 
spectrometry for clinical applications. 
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Figure 1 
Workflows in cancer research for LC-MS-based proteomics. 
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 Figure 2 
Annotated illustration of the steps involved in sample preparation and data acquisition for MALDI MSI of a 
tissue sample applying the ‘microprobe’ approach. Reprinted from Biochimica et Biophysica Acta (BBA) 
Proteins and Proteomics, 1844, Brian Flatley, Peter Malone, Rainer Cramer, MALDI mass spectrometry in 
prostate cancer biomarker discovery, 940-949, Copyright (2014), with permission from Elsevier [40]. 
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Figure 3 
Schematic of the REIMS system allowing intra-operative analysis by thermal desorption of material from 
biological material with an electrosurgical tool. The aerosol is transported through a length of tubing and 
analysed by QTOF MS. Differences between mass profiles, and thus the biological material, can be 
evaluated within seconds with multivariate statistical analysis. 
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